Aptamers have been identified that bind to the sGP protein in ebola virus. The aptamers are single stranded DNA aptamers. The aptamers have high specificity and bind sGP in serum samples. The aptamers can be used to detect infection of individuals with ebola virus. Methods for detecting ebola virus in an individual are disclosed.

A reader for a lateral flow test device includes a tray or drawer, extendable from the reader, which receives the test device. The tray includes a calibration test pattern affixed or printed thereon placed proximate to the test device and in alignment with the axis of the test device. As the tray is closed and the test device is inserted to the reader, the calibration test pattern is first read by an optics unit including a photodiode. The resulting photodiode output provides a calibration curve S that the reader then uses to correct for any non-linear response of the reader's optical or electronic systems, thus insuring that every reader will yield the same readout for a given test cartridge, despite reader-to-reader variations or reader degradation with time. One use of the reader is for detection of SARS-CoV-2 infection.

The present disclosure relates to methods, systems, kits, and computer-program products for the quantification of antibodies. In an embodiment of the disclosure, the method comprises generating a standard curve and subsequently utilizing the standard curve to quantitate an antibody of interest. Also disclosed are systems, kits, and computer-program products for the quantitative detection of an antibody of interest in a sample using the methods described herein. In certain embodiments, the standard curve is developed using an immunoglobulin (e.g., IgG) that does not specifically recognize the antigen(s) recognized by the antibody of interest but is of the same immunoglobulin class as the antibody of interest (IgG). In this way, an applicable standard curve may be generated for various isolates of the antibody of interest.

The invention is directed to methods and systems for early detection of viral diseases, and more specifically to systems and methods for early detection of viral diseases that are capable of detecting very low viral loads, such as for example and not limitation, SARS-CoV-2 loads.

The present disclosure provides assays, such as lateral flow assays, and components thereof for detection of an analyte, e.g., a neutralizing antibody, that blocks binding of a first molecular component and a second molecular component of a molecular binding pair. In some embodiments, the disclosed assays and components thereof enable the rapid detection of a SARS-CoV-2 neutralizing antibody in a sample from an individual. Also provided in other aspects of the disclosure are devices, methods of making and using, and kits of the assays described herein.

The present disclosure is directed to assays for detecting at least one of a SARS-CoV-2 specific antibody, a SARS-COV-2 specific immunoglobulin, and a monoclonal response to single linear neutralizing epitopes within SARS-CoV-2 spike protein, wherein the assay includes a plasmonic-fluor. The assays include multiplexed and ultrafast assays.

In one aspect, provided herein are antibodies that bind to Zika virus non-structural protein 1 (NS1) and compositions comprising the same. In a specific embodiment, such antibodies or compositions thereof may be used to passively immunize a subject against Zika virus. In another embodiment, such antibodies or compositions thereof may be used to diagnose a Zika virus infection. In another aspect, provided herein are recombinant NS 1 polypeptides and compositions comprising the same that may be used to immunize a subject against Zika virus disease.

The present invention provides: a recombinant expression vector comprising a gene encoding a porcine parvovirus VP2 protein; a recombinant plant or a recombinant insect cell transformed with the vector; and a vaccine composition for a porcine parvovirus and a composition for diagnosing porcine parvovirus, both of which contain a porcine parvovirus VP2 protein obtained from the recombinant plant or the recombinant insect cell. When the recombinant plant or recombinant insect cell of the present invention is used, the porcine parvovirus antigenic protein can be produced with high efficiency, and the porcine parvovirus antigenic protein production method using the recombinant plant or recombinant insect cell has excellent safety and stability compared with other antigen production methods.

The present invention relates to killed/inactivated and/or recombinant Senecavirus A immunogenic compositions and vaccines, and methods of preventing or treating animals in need of with such an immunogenic compositions and vaccines.

The present disclosure provides methods for detecting cell-mediated immunity to SARS-CoV-2 in a subject, methods for detecting a cell-mediated immune response against SARS-CoV-2 in a subject and methods for determining if a vaccine against SARS-CoV-2 elicits a cell-mediated immune response in a subject, comprising administering to the skin of the subject one or more peptides.